Publication | Closed Access

Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response

Hematological MalignancyChronic Myeloid LeukemiaMedicineMixed-phenotype Acute LeukemiaComplete Molecular ResponseHematologyImmunologyPathologyImatinib Mesylate DiscontinuationAdult T-cell Leukemia-lymphomaImmunotherapyOncologyMyeloid Neoplasia